In Nplate® (romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.

Nplate (romiplostim) is a prescription drug that works to treat thrombocytopenia by activating bone marrow cells to make more platelets. Your response to this drug may vary based on your medical ...

Nplate (romiplostim) can cause side effects that range from mild to serious. More common side effects include joint pain and dizziness. If side effects from Nplate become difficult to tolerate, talk ...

Nplate (romiplostim) is a subcutaneous injection given by a healthcare professional. Your dose depends on your body weight. For ITP, Nplate is given once per week. For radiation sickness, it’s given ...

How Does It Work for ITP? There is no cure for ITP. Its symptoms can vary from person to person, with some people not having any symptoms. Because ITP causes low platelets, the main side effects that ...

Nplate is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than chronic ITP. In the U.S., Nplate is available only through a restricted ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

As with other drugs, Nplate (romiplostim) can cause side effects such as dizziness and insomnia. If you are not able to tolerate the side effects of Nplate, talk with your doctor or pharmacist. Nplate ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen Inc. (NASDAQ:AMGN - News) today announced that the U.S. Food and Drug Administration (FDA) has approved Nplate TM (romiplostim), the first and only ...

"Nplate may offer the potential for long-term effective treatment in patients who wish either to avoid or defer a splenectomy." Nplate Study Shows Favorable Benefit: Risk Profile for Chronic ITP ...

Amgen’s Nplate (romiplostim) has demonstrated efficacy in treating thrombocytopaenia among gastrointestinal (GI) cancer patients, as Phase III RECITE results are presented at ASCO 2025. In the Phase ...